AR126847A1 - Procesos de purificación por cromatografía de intercambio catiónico de flujo continuo para conjugados anticuerpo-fármaco - Google Patents
Procesos de purificación por cromatografía de intercambio catiónico de flujo continuo para conjugados anticuerpo-fármacoInfo
- Publication number
- AR126847A1 AR126847A1 ARP220102261A ARP220102261A AR126847A1 AR 126847 A1 AR126847 A1 AR 126847A1 AR P220102261 A ARP220102261 A AR P220102261A AR P220102261 A ARP220102261 A AR P220102261A AR 126847 A1 AR126847 A1 AR 126847A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- cation exchange
- purification
- exchange chromatography
- continuous flow
- Prior art date
Links
- 238000000746 purification Methods 0.000 title abstract 8
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 7
- 238000005277 cation exchange chromatography Methods 0.000 title abstract 4
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000463 material Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 239000010779 crude oil Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163236170P | 2021-08-23 | 2021-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126847A1 true AR126847A1 (es) | 2023-11-22 |
Family
ID=83271094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102261A AR126847A1 (es) | 2021-08-23 | 2022-08-22 | Procesos de purificación por cromatografía de intercambio catiónico de flujo continuo para conjugados anticuerpo-fármaco |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240277859A1 (enExample) |
| EP (1) | EP4392433A1 (enExample) |
| JP (1) | JP2024532238A (enExample) |
| KR (1) | KR20240046733A (enExample) |
| CN (1) | CN117881686A (enExample) |
| AR (1) | AR126847A1 (enExample) |
| AU (1) | AU2022332274A1 (enExample) |
| CA (1) | CA3229079A1 (enExample) |
| IL (1) | IL310556A (enExample) |
| MX (1) | MX2024002133A (enExample) |
| TW (1) | TW202323268A (enExample) |
| WO (1) | WO2023028446A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118290513B (zh) * | 2024-06-05 | 2025-03-14 | 东曜药业有限公司 | 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1869065T3 (da) | 2005-03-11 | 2020-06-08 | Wyeth Llc | Fremgangsmåde til kromatografi med svag opdeling |
| WO2012059308A1 (en) * | 2010-11-01 | 2012-05-10 | Dsm Ip Assets B.V. | Single unit ion exchange chromatography antibody purification |
| SG10201701224UA (en) | 2012-03-12 | 2017-04-27 | Merck Patent Gmbh | Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode |
| CN104208719B (zh) * | 2014-09-24 | 2017-05-03 | 北京天广实生物技术股份有限公司 | 一种抗体偶联药物的阳离子交换层析纯化方法 |
| US20180311375A1 (en) * | 2017-04-27 | 2018-11-01 | Cadila Healthcare Limited | Process of preparing antibody-drug conjugate |
-
2022
- 2022-08-22 JP JP2024510666A patent/JP2024532238A/ja active Pending
- 2022-08-22 US US18/682,046 patent/US20240277859A1/en active Pending
- 2022-08-22 AR ARP220102261A patent/AR126847A1/es unknown
- 2022-08-22 MX MX2024002133A patent/MX2024002133A/es unknown
- 2022-08-22 CN CN202280056541.9A patent/CN117881686A/zh active Pending
- 2022-08-22 CA CA3229079A patent/CA3229079A1/en active Pending
- 2022-08-22 EP EP22768589.8A patent/EP4392433A1/en active Pending
- 2022-08-22 IL IL310556A patent/IL310556A/en unknown
- 2022-08-22 AU AU2022332274A patent/AU2022332274A1/en active Pending
- 2022-08-22 KR KR1020247006568A patent/KR20240046733A/ko active Pending
- 2022-08-22 WO PCT/US2022/075252 patent/WO2023028446A1/en not_active Ceased
- 2022-08-22 TW TW111131425A patent/TW202323268A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022332274A1 (en) | 2024-02-15 |
| MX2024002133A (es) | 2024-03-06 |
| EP4392433A1 (en) | 2024-07-03 |
| IL310556A (en) | 2024-03-01 |
| US20240277859A1 (en) | 2024-08-22 |
| CA3229079A1 (en) | 2023-03-02 |
| KR20240046733A (ko) | 2024-04-09 |
| TW202323268A (zh) | 2023-06-16 |
| CN117881686A (zh) | 2024-04-12 |
| WO2023028446A1 (en) | 2023-03-02 |
| JP2024532238A (ja) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES8504461A1 (es) | Un procedimiento para obtener un polidoma. | |
| CL2024002235A1 (es) | Anticuerpo anti-cd73 humano; método de producción; composición farmacéutica; y su uso. | |
| AR069097A1 (es) | Purificacion de anticuerpos por cromatografia de intercambio cationico | |
| AR063086A1 (es) | Anticuerpos humanos que se unen a cxcr4 y usos de los mismos | |
| BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
| GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
| MX346912B (es) | Metodos para mejorar terapia con anticuerpos antitumor. | |
| PE20191436A1 (es) | Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos | |
| ES2013338A6 (es) | Un procedimioento para la obtencion de una linea celular hibrida productora de un anticuerpo monoclonal que se une especificamente a una proteina de superficie celular de un fagocito. | |
| AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| AR064337A1 (es) | Anticuerpos humanos que enlazan con cd19 y sus usos | |
| AR085624A2 (es) | Anticuerpos de p-caderina | |
| DK1232392T3 (da) | Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring | |
| AR047611A1 (es) | Formulaciones liquidas de anticuerpos anti-egfr altamente concentradas | |
| ES2130121T3 (es) | Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva. | |
| MX2018001686A (es) | Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco. | |
| MX2017008410A (es) | Reduccion selectiva de residuos cisteina en anticuerpos il-17. | |
| CL2025002872A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| AR121921A1 (es) | Composiciones y métodos de tratamiento del cáncer con receptores de antígeno quimérico | |
| CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| BR112023016717A2 (pt) | Anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47, molécula de ácido nucleico, e, uso do anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47 | |
| Leonard et al. | Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia; current evidence, and improving outcomes going forward | |
| MX2025012641A (es) | Anticuerpo anti-ptk7 y usos del mismo |